PDF Cover

Advanced Cancer Diagnostics Market

The market for Advanced Cancer Diagnostics was estimated at $63.5 billion in 2025; it is anticipated to increase to $99.4 billion by 2030, with projections indicating growth to around $156 billion by 2035.

Report ID:DS1806024
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Advanced Cancer Diagnostics
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Advanced Cancer Diagnostics Market Outlook

Revenue, 2025

$63.5B

Forecast, 2035

$155B

CAGR, 2026 - 2035

9.4%

The Advanced Cancer Diagnostics industry revenue is expected to be around $63.5 billion in 2026 and expected to showcase growth with 9.4% CAGR between 2026 and 2035. Advanced cancer diagnostic techniques are highly significant in the fight against cancer worldwide, due to the emphasis by oncologists on treatment which is both effective and cost efficient and early diagnosis. Growing cancer incidence rates, the increasing adoption of precision oncology and the growing field of personalised cancer care, are all major drivers of the expansion of the cancer diagnostics market. The trend is being driven by developments in several fields including liquid biopsy platforms, genomic profiling, AI powered imaging and molecular diagnostics. This has resulted in deeper integration of these technologies into cancer care.

A comprehensive range of molecular diagnostics tests and tools, including molecular and genetic diagnostics, tests for cancer biomarkers, next generation DNA sequencing methods and companion diagnostic tools, plus imaging and digital pathology are available through Advanced Cancer Diagnostics. Together breast and lung cancer account for approximately 57.4% of the market demand, with further growth anticipated in the region's of colorectal, prostate and leukemic cancers. In these latter conditions, there is an increasing use of both advanced cancer diagnostic techniques and analysis of the genetic makeup of the tumour. The molecular and genomic diagnostics sector dominated the market in 2025 with $19.29 billion revenue. This was due to the fact that clinicians were favouring the use of multi gene panels for comprehensive profiling of tumours and the monitoring of patients through minimally invasive techniques. As a consequence of recent technological advancements, liquid biopsy is increasingly being used for the purpose of assessing treatment response and also for the surveillance of cancer recurrence. Moreover, interoperability of diagnostic information across different healthcare networks is set to improve, and decentralised testing is also becoming more prevalent. Advanced cancer diagnostics are likely to remain central to cancer treatment.

Advanced Cancer Diagnostics market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Advanced Cancer Diagnostics Market Outlook

Market Key Insights

  • The Advanced Cancer Diagnostics market is projected to grow from $63.5 billion in 2025 to $156 billion in 2035. This represents a CAGR of 9.4%, reflecting rising demand across Breast Cancer, Lung Cancer, and Prostate Cancer.

  • Market leaders shaping the competitive landscape of this industry are Thermo Fisher Scientific, Roche Diagnostics and Illumina Inc.

  • The US and France will see the most significant growth in the field of advanced cancer diagnostics over the forecast period. This growth will occur at an estimated compound annual rate of 6.9 9.9%.

  • Markets which are developing, such as those in India, Brazil and South Africa, are expected to experience the most growth, at a rate of between 9% and 11.8% compound annually.

  • The expected shift towards personalised medicine is likely to contribute around $8 billion to the cancer diagnostics market growth by 2030.

  • The market for advanced cancer diagnostics will grow by nearly $92.4 billion by the year 2035, as industry leaders seek out new lung cancer and colorectal cancer applications.

  • With increasing prevalence of cancer worldwide combined with rising demand for early detection technologies, and technological advancements in molecular profiling and liquid biopsy techniques, the advanced cancer diagnostics market is expected to expand 146% between 2025 and 2035.

advanced cancer diagnostics market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Advanced Cancer Diagnostics - Country Share Analysis

Opportunities in the Advanced Cancer Diagnostics

Integrating companion diagnostic tools, next generation sequencing and liquid biopsy in standard American cancer care is also enabling precision oncology. Molecular diagnostics, by which $19 billion is generated globally in 2025 and $31 billion in 2030, are at present the sector which is growing at the quickest rate. There is significant potential in partnerships between academic research institutions, pharmaceutical companies and diagnostic laboratories for biomarker discovery. These partnerships can lead to a diverse range of cancer diagnostic products and robust clinical tools to aid targeted therapies.

Growth Opportunities in North America and Asia-Pacific

Advanced cancer diagnostics in North America is a sector that is supported by well established insurance reimbursement, a strong commitment to precision cancer treatment, plus an extensive network of cancer detection services. Mammography has been widely adopted in this region because of the large number of breast cancer cases and it is complemented by the increasing demand for molecular screening tools which can be used to help decide which cancer treatments will be most effective. A high level of competition is seen in the in vitro diagnostics and oncology imaging industries, as well as within the field of genomic laboratories. This is driving innovation in the fields of liquid biopsy, genetic analysis and AI assisted treatment monitoring and risk assessment. These opportunities revolve around the use of integrated diagnostic pathways which link breast cancer diagnostics with imaging technologies and genetic information, and also involve increased point of care testing at clinics in order to screen women who are in lower socio economic groups. Investments should be made in scalable and interoperable systems which tie in pathology, radiology and genetic information. This would allow hospitals and laboratories to differentiate through cancer services, tailored to value based care systems.
The region of the Asia Pacific is witnessing a rapid adoption of Advanced Cancer Diagnostics. This growth is largely due to an expansion in healthcare systems and an increase in oncology capacity. Lung cancer has become the most significant application in this region. This is primarily due to the high incidence of lung cancer which is often linked to smoking prevalence and urban air pollution, along with the fact that it is usually diagnosed at a late stage. The factors driving the market for these tests are increasing healthcare costs, a national screening programme and a rapid adoption of targeted treatments which rely on accurate diagnostic techniques at the molecular level and companion diagnostics. The latter applies particularly to EGFR and ALK biomarkers. In the competitive market, a mix of international companies and small regional producers supply low cost diagnostic tests, imaging equipment and liquid biopsy systems, where the pricing of the products, the region's they cover with their services and how the technology is used are the key distinguishing factors. There are significant opportunities in the implementation of cost effective and high capacity genomic analysis for lung cancer, in the use of AI for cancer diagnosis to give imaging services priority and the roll out of modular cancer diagnostic systems. By forging alliances with local public health programs, oncology networks and diagnostic laboratories, service providers will be able to establish themselves in these rapidly expanding cancer diagnostic and screening markets.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Cancer Worldwide Combined with Rising Demand for Early Detection Technologies

The advanced cancer diagnostics market is also strongly driven by the rising global incidence of cancer and the growing demand for early detection technologies. According to global health data, cancer cases continue to escalate due to aging populations, lifestyle changes and environmental factors. This increasing disease burden emphasizes the need for accurate and timely diagnostic tools that can also detect cancer at its asymptomatic stages, improving survival rates and treatment outcomes. Alongside this, there is also greater awareness among patients and healthcare providers about the benefits of early detection, particularly for cancers such as breast, lung and prostate. Early detection technologies including low‑dose computed tomography, digital mammography, genetic biomarker assays and liquid biopsy platforms offer high sensitivity and specificity, enabling clinicians to identify malignancies earlier than traditional methods. This dual force of rising cancer prevalence and the demand for early, minimally invasive diagnostics is also expanding adoption of advanced imaging systems, molecular profiling technologies and next‑generation sequencing assays across clinical and outpatient settings, thus fueling market growth. 
Another key driver for the advanced cancer diagnostics market is also the rapid evolution of molecular profiling and liquid biopsy technologies. These innovations enable non‑invasive detection and monitoring of tumor‑specific biomarkers, including circulating tumor DNA and RNA, from blood samples. Liquid biopsies enhance precision medicine by providing real‑time insights into tumor evolution, therapy response and resistance mechanisms without the need for repeated tissue biopsies. As a result, they are also increasingly integrated into clinical workflows for cancers such as lung, breast and colorectal, driving demand for more sensitive, high‑throughput genomic and proteomic assays and strengthening the market’s technological foundation. 
02

Restraint: High Diagnostic Costs and Inconsistent Reimbursement Policies Limit Widespread Adoption

One significant restraint facing the advanced cancer diagnostics market is the high cost of advanced imaging systems, genomic profiling tests, and liquid biopsy assays coupled with inconsistent insurance reimbursement. Many next‑generation sequencing panels and PET‑CT scans are expensive, forcing patients or healthcare systems to delay or decline testing. Limited coverage for newer diagnostics reduces demand from cost‑sensitive clinics and patients, which suppresses revenue growth and slows broader clinical adoption despite demonstrated clinical value.
03

Opportunity: Population-based early cancer screening initiatives across China and India using advanced imaging-based diagnostics and Digital histopathology and cytology services for community oncology clinics in underserved Latin American markets

Across China and India, there is increasing population screening for a number of diseases. As a result there is growing demand for early cancer diagnosis techniques. The imaging diagnostics market worldwide is predicted to grow from $17.32 billion in 2025 to $26.65 billion in 2030. This sector will expand quickly due to an increase in the use of low dose modalities and AI powered imaging systems in secondary and tertiary healthcare facilities. A large untapped market exists in cloud enabled, image analysis solutions as well as low cost point of care testing bundles for public health organisations that deal in high volumes, these can improve healthcare access for people in urban and rural region's who have been underserved previously.
Across Latin America many cancer clinics in low income communities suffer from a severe shortage of highly trained specialist pathologists, this makes diagnosing advanced cancers very difficult. Digital diagnostics in cytology and histopathology are expected to witness a sizeable growth, rising from $15.1 billion in 2025 to $22.9 billion by 2030. The market for diagnostic services is likely to expand in region's including cloud based image management, telepathology, and cytology, all of which can provide quicker diagnoses and support treatments at hospitals and public labs.
04

Challenge: Complex Regulatory Requirements and Variability in Clinical Validation Slow Market Entry

Another key challenge in the advanced cancer diagnostics space is the stringent and complex regulatory landscape across different regions, as well as variability in clinical evidence standards. Securing approval for novel biomarkers and diagnostic platforms requires extensive clinical validation and long review timelines, which increases development costs and delays commercialization. This can deter smaller diagnostics firms, reduce competitive diversity, and slow the pace of innovation, affecting overall market dynamics.

Supply Chain Landscape

1

Molecular Diagnostics Inputs

Thermo Fisher ScientificRoche DiagnosticsIllumina Inc
2

Advanced Cancer Diagnostics

Roche DiagnosticsSiemens HealthineersGE HealthCare
3

Genomic Sequencing Systems

Illumina Inc.Thermo Fisher ScientificGE HealthCare
4

Precision Oncology Users

HospitalsOncology ClinicsDiagnostic Laboratories
Advanced Cancer Diagnostics - Supply Chain

Use Cases of Advanced Cancer Diagnostics in Breast & Lung

Breast Cancer : In breast cancer, advanced diagnostics leverage digital mammography, digital breast tomosynthesis, molecular assays, and biomarker testing to improve early detection and accurate staging. Mammography remains foundational in screening, while immunohistochemistry (IHC) and gene expression tests refine diagnosis by evaluating hormone receptor and HER2 status, guiding targeted therapies and personalized treatment plans. Leading providers including Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific and Hologic are prominent in imaging systems and molecular assays, combining robust clinical validation with global distribution. Their strength lies in integrating imaging with companion diagnostics for precision oncology, helping clinicians detect breast tumors earlier and improve outcome monitoring. Ongoing innovations in AI‑enhanced image analysis and liquid biopsy further advance sensitivity and specificity, particularly in high‑risk populations.
Lung Cancer : For lung cancer, advanced diagnostics combine low‑dose computed tomography, combines Positron Emission Tomography imaging, molecular profiling and liquid biopsy to detect tumors earlier and identify actionable genetic mutations such as EGFR, ALK and KRAS. LDCT screening programs and high‑resolution imaging enable clinicians to identify nodules at earlier stages, while next‑generation sequencing and circulating tumor DNA assays support personalized treatment decisions. Companies like GE HealthCare, Illumina, Roche Diagnostics and Siemens Healthineers lead with integrated platforms that support imaging and molecular testing workflows. These technologies help improve prognosis by enabling targeted therapy selection and real‑time monitoring of treatment response. Liquid biopsy platforms also facilitate minimally invasive genomic profiling, crucial for advanced or metastatic cases.
Prostate Cancer : In prostate cancer, diagnostics increasingly rely on prostate‑specific antigen (PSA) testing, MRI, and PET imaging agents targeting PSMA along with genomic assays that refine risk stratification and guide therapeutic strategies. Traditional PSA screening remains widespread for early indication of elevated risk, while multiparametric MRI enhances lesion characterization and reduces unnecessary biopsies. Recent regulatory advancements like FDA approval of PSMA PET agents such as Gozellix improve lesion detection specificity and clinical utility. Molecular panels and liquid biopsy tests further support personalized care by identifying prognostic biomarkers and aiding treatment planning. Key players including Abbott, Roche Diagnostics, Thermo Fisher Scientific and Siemens Healthineers are advancing comprehensive diagnostic portfolios that combine sensitive biomarker tests with advanced imaging modalities to improve prostate cancer detection and monitoring.

Recent Developments

The advanced cancer diagnostics market is rapidly evolving with the growing adoption of liquid biopsy, molecular profiling, and AI‑assisted imaging technologies that enhance early detection and precision oncology. Key players are expanding next‑generation sequencing and circulating tumor DNA assay portfolios to support personalized treatment strategies. These innovations improve diagnostic sensitivity and specificity, drive oncology workflow efficiency, and support biomarker‑guided therapy decisions, reinforcing demand across hospitals, diagnostic laboratories, and precision medicine programs worldwide.

May 2025 : Roche secured FDA clearance for the VENTANA MET (SP44) RxDx Assay, the first companion diagnostic to detect MET protein expression in non‑squamous NSCLC patients, aiding selection for targeted therapy.
August 2024 : Illumina’s TruSight Oncology Comprehensive test gained FDA approval with companion diagnostic indications, enabling broad genomic profiling across solid tumors to match patients to targeted treatments.
October 2025 : Bio‑Rad Laboratories partnered with Gencurix to distribute CE‑IVD Droplex ddPCR oncology testing kits across Europe, expanding access to sensitive circulating tumor biomarker assays.

Impact of Industry Transitions on the Advanced Cancer Diagnostics Market

As a core segment of the Other Healthcare industry, the Advanced Cancer Diagnostics market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Personalized Medicine and Rise of Liquid Biopsy have redefined priorities across the Other Healthcare sector, influencing how the Advanced Cancer Diagnostics market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Towards Personalized Medicine

Personalised medicine is the driver of a shift towards a more targeted approach in the advanced cancer diagnostics sector, where a patients individual characteristics are used to provide a diagnosis. This shift is expected to increase market revenue by $8 billion by 2030. As precision cancer medicine and the genetic testing of tumours becomes a more normal part of healthcare, companies are focusing their efforts on creating diagnostic tools that are capable of effectively categorising the risk posed by cancer, of assisting in the choice of the best treatment and of spotting any cancer remaining after treatment which can cause a patient to ill again. The shift to precision medicine is driving investment in technologies including companion diagnostics and liquid biopsy. This has led to earlier treatments and more suitable treatment options being selected across alls of cancer. Companies that adapt their products and services to match clinically validated workflows which make use of biomarkers will take advantage of a large share of the market. This is due to health care providers and insurance companies offering higher payments for diagnostic tools which prove that they reduce costs and improve outcomes for cancer patients.
02

Rise of Liquid Biopsy

The advanced cancer diagnostics market is undergoing a notable shift with the rise of liquid biopsy technologies, which enable non‑invasive detection and monitoring of cancer through blood, urine, or other body fluids. Unlike traditional tissue biopsies, liquid biopsies reduce patient discomfort, minimize procedure-related complications, and allow repeated sampling to track tumor progression or treatment response. This transition is impacting associated industries such as molecular diagnostics, laboratory services, and precision oncology, prompting companies to develop high-sensitivity circulating tumor DNA assays and next-generation sequencing panels. Providers like Guardant Health, Illumina, Roche Diagnostics, and Thermo Fisher Scientific are expanding liquid biopsy platforms, enhancing workflow efficiency for oncology clinics and research institutions. The trend supports faster decision-making for targeted therapies and accelerates integration of personalized medicine approaches, driving adoption across hospitals, diagnostic labs, and contract research organizations globally.